LivingGLP1
Study S003268

Evaluation of the Bioequivalence of RAY1225 Injection in Healthy Participants in a Single-center, Randomized, Open-label, Parallel Study

Registration

Registration
NCT07827027
Study type
INTERVENTIONAL
Allocation
RANDOMIZED
Phase
PHASE1
Masking
NONE
Status
NOT_YET_RECRUITING
Enrollment
68
Start
2026-09-21
Primary completion
2026-11-05
Lead sponsor
Guangdong Raynovent Biotech Co., Ltd
Conditions
Basic Science
Interventions
DRUG:RAY1225
Results posted
FALSE
Individual participant data sharing
NO

Registered primary outcomes

  • Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve (AUC) of RAY1225 From Time Zero to T (AUC[0-t]) [Baseline through Day 43]
  • PK: Maximum Concentration of RAY1225 [Baseline through Day 43]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.